<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339401</url>
  </required_header>
  <id_info>
    <org_study_id>CMX001-999</org_study_id>
    <nct_id>NCT03339401</nct_id>
  </id_info>
  <brief_title>The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation</brief_title>
  <acronym>AdAPT</acronym>
  <official_title>An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chimerix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chimerix</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety, overall tolerability, and antiviral activity of
      &quot;short course&quot; BCV therapy, as compared with current standard of care (SoC), for the
      treatment of adenovirus (AdV) infections in high-risk (i.e., T cell depleted) pediatric
      allogeneic hematopoietic cell transplant (HCT) recipients. A virologic response-driven
      approach to the duration of treatment will be evaluated, in which subjects randomized to BCV
      therapy are treated until AdV viremia is confirmed as undetectable or until a maximum of 16
      weeks of therapy, whichever occurs first.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated due to low enrollment rate
  </why_stopped>
  <start_date type="Actual">December 22, 2017</start_date>
  <completion_date type="Actual">May 10, 2019</completion_date>
  <primary_completion_date type="Actual">May 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome is the time-averaged area under the concentration-time curve (AAUC) for plasma AdV viremia (log10 copies/mL).</measure>
    <time_frame>randomization through16 weeks</time_frame>
    <description>From randomization through Week 16, time-averaged area under the concentration-time curve (AAUC) for plasma AdV viremia (log10 copies/mL).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Adenovirus</condition>
  <arm_group>
    <arm_group_label>Brincidofovir (BCV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SOC</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>SOC per study center guidelines</description>
    <arm_group_label>Standard of Care (SOC)</arm_group_label>
    <other_name>SOC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brincidofovir</intervention_name>
    <description>BCV</description>
    <arm_group_label>Brincidofovir (BCV)</arm_group_label>
    <other_name>BCV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged at least 2 months and less than 26 years-old on Day 1 (US only) ages 2 months or
             less than 18 years old on day one (ROW) AND

          2. Have received a T cell-depleted allogeneic (i.e., non-autologous) HCT within the
             previous 100 days.

          3. First detectable AdV DNA plasma viremia since the qualifying transplant occurred
             within 21 days prior to Day 1.

          4. Have EITHER:

        A) Confirmed AdV viremia of ≥ 1000 copies/mL and rising, defined as two consecutive AdV DNA
        polymerase chain reaction (PCR) test results ≥ 1000 copies/mL from the designated central
        virology laboratory, with the second result being greater than the first. The second sample
        must be drawn at least 48 hours after the first sample and no more than 7 days prior to Day
        1. OR B) Single AdV viremia measurement of ≥ 10,000 copies/mL reported by the designated
        central virology laboratory from a sample drawn no more than 7 days prior to Day 1.

        Exclusion Criteria:

          1. Any CTCAE Grade 4 diarrhea (i.e., life-threatening consequences with urgent
             intervention indicated) within 7 days prior to Day 1

          2. Any CTCAE Grade 2 or 3 diarrhea (i.e., increase of ≥ 4 stools per day over baseline),
             unless attributed to AdV, within 7 days prior to Day 1

          3. NIH Stage 4 acute GVHD of the skin (i.e., generalized erythroderma with bullous
             formation) within 7 days prior to Day 1

          4. NIH Stage 2 or higher acute GVHD of the liver (i.e., bilirubin &gt; 3 mg/dL [SI: &gt; 51
             μmol/L]) within 7 days prior to Day 1

          5. NIH Stage 2 or higher acute GVHD of the gut (i.e., diarrhea &gt; 556 mL/m2/day, or severe
             abdominal pain with or without ileus) within 7 days prior to Day 1

          6. Active malignancy (with the exception of non-melanoma skin cancer), including relapse
             or progression of the underlying disease for which qualifying transplant was performed

          7. Use of vasopressors within 7 days prior to Day 1

          8. PT-INR &gt; 2x upper limit of normal reference range (ULN) in the absence of
             anticoagulation within 7 days prior to Day 1

          9. Requirement for mechanical ventilation within 7 days prior to Day 1, or sustained
             oxygen delivery for &gt; 24 hours within 7 days prior to Day 1, or any oxygen requirement
             within 48 hours prior to Day 1

         10. Estimated creatinine clearance &lt; 30 mL/min or use of renal replacement therapy (e.g.,
             hemodialysis, continuous renal replacement therapy, peritoneal dialysis) within 7 days
             prior to Day 1

         11. ALT &gt; 5x ULN, AST &gt; 5x ULN, or total bilirubin &gt; 3 mg/dL [SI: &gt; 51 μmol/L] within 7
             days prior to Day 1

         12. Human immunodeficiency virus (HIV) infection as detected through any laboratory method
             (e.g., enzyme-linked immunosorbent assay, Western Blot, RNA PCR). [Note: Testing to
             confirm the absence of HIV infection is required at screening unless testing was
             performed by the local laboratory within 6 months prior to screening.]

         13. Females who are pregnant or breastfeeding or planning to become pregnant within 90
             days after their last anticipated dose of BCV

         14. Receiving or anticipated to receive medications prohibited in the protocol.

         15. Hypersensitivity (not including renal dysfunction or eye disorder) to CDV or to BCV or
             its formulation excipients

         16. Participation in another interventional clinical trial unless prior approval has been
             received from the Chimerix Medical Monitor (or designee).

         17. Received any cell-based anti-AdV therapy within 6 weeks prior to Day 1 or previously
             received an anti-AdV vaccine at any time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joseph M. Sanzari Childrens Hospital-Regional Cancer Care</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington-Seattle Childrens Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHOPe-Institut d'Homatologie et d'Oncologie Pediatrique</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Robert Debre</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik fur Kinder-und Jugendmedizin</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Wurttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. von Haunersches Kinderspital, Abteilung fur Padiatrische</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady's Children Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D12 N512</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione MBBM-CTMO Pediatrico</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesu</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center (LUMC)</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Maxima Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwerstytecki Azpital Kliniczny we Wroclawiu</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnoslaskie</state>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle-upon-Tyne Hospitals-Great Childrens Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyneside</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Childrens Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Children's Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Marys Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <zip>WCIN 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Childrens Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoviridae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

